Explore our comprehensive portfolio that addresses the complete care continuum for many of the world’s most threatening diseases. 

Discover the stories of pioneers pushing the boundaries of what’s possible in healthcare to help improve people’s lives around the world.

Patient-centered innovation has been and always will be at the core of our company. Dive deeper into our fascinating technologies.

We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably. Learn more about our purpose, our innovation leadership, our culture, and our strategy.

  1. Home

  2. Press center
  3. Press releases

  4. Siemens Healthineers demonstrates strength in a challenging environment and confirms outlook

Press release

Siemens Healthineers demonstrates strength in a challenging environment and confirms outlook 

Siemens Healthineers AG today announces its results for the fiscal year 2022 third quarter that ended June 30, 2022.

Published on August 3, 2022

Q3 Fiscal Year 2022 

  • Continued very good growth in equipment orders, equipment book-to-bill ratio of 1.31
  • Due to markedly lower revenue from rapid COVID-19 antigen tests and a challenging environment, notably COVID-19 related lockdowns in China, comparable decline in revenue of 5.7% from a very good prior-year quarter with 38.9% growth; excluding rapid COVID-19 antigen tests, comparable revenue growth of 0.9%
  • Considerable comparable revenue growth of 8.2% at Varian and 5.8% in Advanced Therapies; Imaging with solid comparable revenue growth of 2.5% 
  • Diagnostics showed a decline in comparable revenue of 23.9%, primarily due to a lower contribution from rapid COVID-19 antigen tests than in the outstanding prior-year quarter
  • Adjusted EBIT margin of 14.7% – negatively impacted by cost increases in particular for procurement and logistics, lockdowns in China, and reduced earnings from rapid COVID-19 antigen tests compared with the prior-year quarter 
  • Adjusted basic earnings per share dropped 24% from the outstanding prior-year quarter to €0.43

Outlook for Fiscal Year 2022

Despite a more challenging environment, we confirm the expectation of comparable revenue growth between 5.5% and 7.5% and adjusted basic earnings per share between €2.25 and €2.35. 

Bernd Montag, CEO of Siemens Healthineers AG:

»Once again, our team delivered a strong quarter despite an environment that was more than challenging. Supply-chain headwinds and pandemic-related lockdowns pushed out some sales into the next quarters, and cost increases burdened profits. Despite these factors, we confirm our outlook.« 


Download Quarterly Statement(pdf, 266.82 KB)

Siemens Healthineers 2022

Siemens Healthineers AG (listed in Frankfurt, Germany: SHL) is shaping the future of healthcare. As a leading medical technology company headquartered in Erlangen, Germany, Siemens Healthineers enables healthcare providers worldwide through its regional companies to increase value by empowering them on their journey towards expanding precision medicine, transforming care delivery, improving the patient experience, and digitalizing healthcare. Siemens Healthineers is continuously developing its product and service portfolio, with AI-supported applications and digital offerings that play an increasingly important role in the next generation of medical technology. These new applications will enhance the company’s foundation in in-vitro diagnostics, image-guided therapy, in-vivo diagnostics and innovative cancer care. Siemens Healthineers also provides a range of services and solutions to enhance healthcare providers’ ability to provide high-quality, efficient care to patients. In fiscal 2021, which ended on September 30, 2021, Siemens Healthineers, which has approximately 66,000 employees worldwide, generated revenue of €18.0 billion and adjusted EBIT of €3.1 billion. Further information is available at www.siemens-healthineers.com.